Skip to content

Calcipotriene

    Brands

    DEA Class; Rx

    Common Brand Names; Dovonex, Calcitrene Ointment, Sorilux

    • Antipsoriatics, Topical

    Topical vitamin D3 analog
    Used for topical symptomatic treatment of chronic plaque psoriasis
    Similar receptor binding affinity as natural vitamin D3

    Indicated for the treatment of plaque psoriasis.

    Hypersensitivity

    Hypercalcemia

    Evidence of vitamin D toxicity

    Topical use on the face

    • Burning
    • Itching
    • Skin irritation
    • Dermatitis
    • Dry skin
    • Erythema
    • Peeling
    • Worsening of psoriasis including facial/scalp
    • Rash

    Hypercalcemia and hypercalciuria reported with topical suspension; if hypercalcemia or hypercalciuria develop, discontinue treatment until parameters of calcium metabolism have normalized; incidence of hypercalcemia and hypercalciuria following topical suspension treatment of more than 8 weeks has not been evaluated

    For cream only: Allergic contact dermatitis has been observed with use of topical calcipotriene; such an observation should be corroborated with appropriate diagnostic patch testing

    No data available on drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes in pregnant women exposed to calcipotriene

    There are no data on the presence of topically administered calcipotriene in human or animal milk, the effects on the breastfed infant, or the effects on milk production

    After topical administration, plasma concentrations of calcipotriene are low, and therefore, concentrations in human milk are likely to be low

    Adults

    100 g/week topically for the cream and lotion; specific maximum dosage information not available for foam or scalp solution.

    Geriatric

    100 g/week topically for the cream and lotion; specific maximum dosage information not available for foam or scalp solution.

    Adolescents

    Specific maximum dosage information not available for foam; safety and efficacy have not been established for the cream, lotion, or scalp solution.

    Children

    4 to 12 years: Specific maximum dosage information not available for foam; safety and efficacy have not been established for the cream, lotion, or scalp solution.
    1 to 3 years: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Calcipotriene 

    topical solution

    • 0.005% (generic)

    topical ointment

    • 0.005% (generic)

    topical cream

    • 0.005% (Dovonex, generic)

    topical foam

    • 0.005% (Sorilux)